The estimated Net Worth of Faheem Hasnain is at least $321 Milion dollars as of 21 June 2024. Mr. Hasnain owns over 372,000 units of Mirati Therapeutics Inc stock worth over $317,453,885 and over the last 19 years he sold MRTX stock worth over $1,141,420. In addition, he makes $2,650,930 as Chairman of the Board at Mirati Therapeutics Inc.
Faheem has made over 17 trades of the Mirati Therapeutics Inc stock since 2006, according to the Form 4 filled with the SEC. Most recently he bought 372,000 units of MRTX stock worth $249,240 on 21 June 2024.
The largest trade he's ever made was buying 878,572 units of Mirati Therapeutics Inc stock on 20 March 2023 worth over $1,001,572. On average, Faheem trades about 35,798 units every 112 days since 2006. As of 21 June 2024 he still owns at least 5,408,073 units of Mirati Therapeutics Inc stock.
You can see the complete history of Mr. Hasnain stock trades at the bottom of the page.
Faheem Hasnain serves as Chairman of the Board of the Company. Mr. Hasnain has served as a member of our Board of Directors and as Chairman of the Board since February 2019. Mr. Hasnain is the Co-Founder and served as Chairman and Chief Executive Officer of Gossamer Bio, Inc. from its inception through July 2018, at which time he became its Executive Chairman. Prior to that, Mr. Hasnain served as President, Chief Executive Officer and as a director of Receptos from November 2010 until the company’s acquisition by Celgene in August 2015. Prior to joining Receptos, Mr. Hasnain was the President and Chief Executive Officer and a director of Facet Biotech Corporation. He held that position from December 2008 until the company’s acquisition by Abbott Laboratories in April 2010. Previously, Mr. Hasnain was President, Chief Executive Officer and a director of PDL BioPharma, Inc. from October 2008 until Facet Biotech was spun off from PDL BioPharma in December 2008. From October 2004 to September 2008, Mr. Hasnain served at Biogen Inc., most recently as Executive Vice President in charge of the oncology/rheumatology strategic business unit. Prior to Biogen, Mr. Hasnain held roles with Bristol-Myers Squibb, where he was President of Oncology Therapeutics Network, and for 14 years at GlaxoSmithKline and its predecessor organizations. He serves as Chairman of the board of directors of SENTE, Inc., Tocagen, Inc. and Vital Therapies, Inc., and as a member of the board of directors of Kura Oncology, Inc. He previously served as Chairman of the board of directors of Ambit Biosciences Corporation and served as a member of the board of directors of Aragon Pharmaceuticals, Seragon Pharmaceuticals, Inc., Pernix Sleep, Inc., Somaxon Pharmaceuticals, Inc. and Tercica, Inc. Mr. Hasnain received a B.H.K. and B.Ed. from the University of Windsor Ontario in Canada.
As the Chairman of the Board of Mirati Therapeutics Inc, the total compensation of Faheem Hasnain at Mirati Therapeutics Inc is $2,650,930. There are 2 executives at Mirati Therapeutics Inc getting paid more, with Charles Baum having the highest compensation of $8,484,390.
Faheem Hasnain is 61, he's been the Chairman of the Board of Mirati Therapeutics Inc since 2019. There are 6 older and 12 younger executives at Mirati Therapeutics Inc. The oldest executive at Mirati Therapeutics Inc is Bruce Carter, 76, who is the Independent Director.
Faheem's mailing address filed with the SEC is 3013, Science Park Road, Torrey Pines, San Diego, San Diego County, California, 92121, United States.
Over the last 11 years, insiders at Mirati Therapeutics Inc have traded over $179,669,845 worth of Mirati Therapeutics Inc stock and bought 8,779,906 units worth $186,410,608 . The most active insiders traders include Healthcare Master Fund Ltd ..., Capital Advisors Llc Aghaza... a Bros. Advisors Lp Baker Bro.... On average, Mirati Therapeutics Inc executives and independent directors trade stock every 22 days with the average trade being worth of $5,885,145. The most recent stock trade was executed by Benjamin Hickey on 16 January 2024, trading 1,597 units of MRTX stock currently worth $94,255.
mirati therapeutics develops molecularly targeted, single agent and immuno-oncology combination therapies intended to treat cancer. mirati's approach combines the three most important factors in oncology drug development, 1) researching and developing drug candidates that target genetic and epigenetic drivers of cancer, 2) designing creative and agile clinical development strategies that select for patients whose tumors are dependent on specific driver alterations, and 3) leveraging a highly accomplished oncology precision medicine leadership team. the mirati team uses a blueprint – proven by their prior work – for developing potential breakthrough cancer therapies, with accelerated development paths, in order to improve outcomes for patients. mirati is advancing three drug candidates through clinical development for multiple oncology indications.
Mirati Therapeutics Inc executives and other stock owners filed with the SEC include: